Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02322255 · ClinicalTrials.gov registry record
A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)
A clinical trial, sponsored by Clementia Pharmaceuticals.
- Completed
- Registry status
- 114
- Enrollment target
NCT02322255 is a clinical trial that has completed, run by Clementia Pharmaceuticals. The registered enrollment target is 114 participants.
The verdict
NCT02322255 has completed, sponsored by Clementia Pharmaceuticals.
- COMPLETED
- Registry status
- 114 participants
- Enrollment target
Study Summary
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in abnormal bone formation in muscles, tendons, and ligaments. Flare-ups begin early in life and may occur spontaneously or after soft tissue trauma, vaccinations, or influenza infections. Recurrent flare-ups progressively restrict movement by locking joints leading to cumulative loss of function and disability. This 3-year, non-interventional, two-part, natural history study is designed to gain insight into total body HO, FOP disease progression, the impact of FOP on subjects' physical functioning, and clinical features and biomarkers that may be useful in the diagnosis and monitoring of disease progression. This natural history study will also provide important information to inform the design of subsequent interventional trials.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2014-12-18 |
| Est. Completion | 2020-04-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02322255
The ClinicalTrials.gov registry entry for NCT02322255 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clementia Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02322255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02322255 about?
NCT02322255 is a clinical study titled "A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)". Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in abnormal bone formation in muscles, tendons, and ligaments. Flare-ups begin early in life and may occur spontaneously or a...
What is the current status of trial NCT02322255?
This trial is currently completed. The enrollment target is 114 participants. The study started on 2014-12-18. Estimated completion is 2020-04-09.
Who is sponsoring clinical trial NCT02322255?
This trial is sponsored by Clementia Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.